Investigations
Hims & Hers Health, Inc.
Overview
Overview
- Deadline:
- Upcoming
| Company Name: | Company Name: Hims & Hers Health, Inc. |
| Stock Symbol: | Stock Symbol: HIMS |
Hims & Hers Health, Inc. (NYSE: HIMS): BFA is investigating Hims & Hers for violations of the federal securities laws in connection with potential false and misleading statements made to investors and a subsequent significant price decline in the stock.
If you incurred losses on your investments in Hims & Hers, you are encouraged to submit your information.
Why is Hims & Hers being Investigated?
Hims & Hers is a telehealth company that provides consumers access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products.
On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” through which Hims & Hers would sell Novo Nordisk’s popular weight loss drug Wegovy.
Less than two months later, on June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in “deceptive marketing” and the illegal “selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” On this news, the price of Hims & Hers stock fell $22.25 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025.
What are my Rights?
If you incurred losses on your investments in Hims & Hers, you are encouraged to submit your information to speak with an attorney about your rights.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
If you incurred losses on your investments in Hims & Hers, you are encouraged to submit your information.
Why is Hims & Hers being Investigated?
Hims & Hers is a telehealth company that provides consumers access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products.
On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” through which Hims & Hers would sell Novo Nordisk’s popular weight loss drug Wegovy.
Less than two months later, on June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in “deceptive marketing” and the illegal “selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” On this news, the price of Hims & Hers stock fell $22.25 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025.
What are my Rights?
If you incurred losses on your investments in Hims & Hers, you are encouraged to submit your information to speak with an attorney about your rights.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.